FDA Approves Lumithera’s Photobiomodulation Device for Dry AMD
Lumithera’s Valeda becomes the first FDA-approved treatment for vision loss caused by dry AMD Dry AMD sufferers in the United…
popular posts
latest posts
![[Internal] Newsroom thumbnail Inflammasome Therapeutics Reports 3 Month Trial Data for Its Dual Inflammasome Inhibitor in Geographic Atrophy](https://piemagazine.org/wp-content/uploads/sites/4/2025/01/Internal-Newsroom-thumbnail-Inflammasome-Therapeutics-Reports-3-Month-Trial-Data-for-Its-Dual-Inflammasome-Inhibitor-in-Geographic-Atrophy-579x326.png)
